Int J Stomatol

Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (5): 584-589.doi: 10.7518/gjkq.2018.05.015

• Reviews • Previous Articles     Next Articles

Therapeutic progress of chronic mucocutaneous candidiasis disease

Lu Feng,Wenxia. Meng()   

  1. Dept. of Oral Medicine, Stomatological Hospital, Southern Medical University, Guangzhou 510280, China
  • Received:2018-03-17 Revised:2018-06-02 Online:2018-09-01 Published:2018-09-20
  • Contact: Wenxia. Meng E-mail:mengwx2008@fox-mail.com
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81500850)

RichHTML

11

PDF (PC)

379

Abstract:

Chronic mucocutaneous candidiasis disease (CMCD) is a special type of Candida albicans infection, which is identified associated with immunodeficiency. The pathogenesis is complex and the treatment is more difficult. Conventional antifungal drugs have failed to meet the clinical demands. With the development of various treatment studies expanding, new molecular agents have shown great potential for the treatment of CMCD. This review summarizes the current status of treatment and future development of CMCD, in order to provide more information for clinicians.

Key words: chronic mucocutaneous candidiasis disease, treatment, molecular agents

CLC Number: 

  • R781.5 +4

TrendMD: 
[1] Papazian CE, Koch R , Monilial granuloma with hypo- thyroidism: report of a case treated with amphotericin B[J]. N Engl J Med, 1960,262:16-18.
doi: 10.1056/NEJM196001072620104
[2] Puel A, Picard C, Cypowyj S , et al. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines[J]. Curr Opin Immunol, 2010,22(4):467-474.
doi: 10.1016/j.coi.2010.06.009
[3] Smeekens SP , Plantinga TS, van de Veerdonk FL, et al. STAT1 hyperphosphorylation and defective IL12R/ IL23R signaling underlie defective immunity in auto- somal dominant chronic mucocutaneous candidiasis[J]. PLoS One, 2011,6(12):e29248.
doi: 10.1371/journal.pone.0029248
[4] Liu L, Okada S, Kong XF , et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis[J]. J Exp Med, 2011,208(8):1635-1648.
doi: 10.1084/jem.20110958
[5] Al Rushood M , McCusker C, Mazer B, et al. Autoso-mal dominant cases of chronic mucocutaneous can-didiasis segregates with mutations of signal transdu-cer and activator of transcription 1, but not of Toll-like receptor 3[J]. J Pediatr, 2013,163(1):277-279.
doi: 10.1016/j.jpeds.2013.02.040
[6] Martinez-Martinez L, Martinez-Saavedra MT , Fue-ntes-Prior P, et al. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis[J]. Mol Immunol, 2015,68(2 Pt C):597-605.
doi: 10.1016/j.molimm.2015.09.014
[7] Soltész B, Tóth B, Shabashova N , et al. New and re-current gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe[J]. J Med Genet, 2013,50(9):567-578.
doi: 10.1136/jmedgenet-2013-101570
[8] Dotta L, Scomodon O, Padoan R , et al. Clinical he-terogeneity of dominant chronic mucocutaneous can-didiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease[J]. Clin Immunol, 2016,164:1-9.
doi: 10.1016/j.clim.2015.12.010
[9] Yamazaki Y, Yamada M, Kawai T , et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody[J]. J Immunol, 2014,193(10):4880-4887.
doi: 10.4049/jimmunol.1401467
[10] Lorenzini T, Dotta L, Giacomelli M , et al. STAT mu- tations as program switchers: turning primary immu-nodeficiencies into autoimmune diseases[J]. J Leukoc Biol, 2017,101(1):29-38.
doi: 10.1189/jlb.5RI0516-237RR pmid: 27803128
[11] Depner M, Fuchs S, Raabe J , et al. The extended clinical phenotype of 26 patients with chronic mucocu- taneous candidiasis due to gain-of-function mutations in STAT1[J]. J Clin Immunol, 2016,36(1):73-84.
doi: 10.1007/s10875-015-0214-9
[12] Puel A, Cypowyj S, Bustamante J , et al. Chronic mu-cocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity[J]. Science, 2011,332(6025):65-68.
doi: 10.1126/science.1200439 pmid: 21350122
[13] McDonald DR . Th17 deficiency in human disease[J]. J Allergy Clin Immunol, 2012,129(6):1429-1437.
doi: 10.1016/j.jaci.2012.03.034 pmid: 3388506
[14] Petersen EA, Alling DW, Kirkpatrick CH , Treatment of chronic mucocutaneous candidiasis with ketoco-nazole: a controlled clinical trial[J]. Ann Intern Med, 1980,93(6):791-795.
doi: 10.7326/0003-4819-93-6-791
[15] Mobacken H, Moberg S , Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis. A prospective 3-year trial[J]. Dermatologica, 1986,173(5):229-236.
doi: 10.1159/000249259 pmid: 3100354
[16] Ahonen P, Myllärniemi S, Kahanpää A , et al. Keto-conazole is effective against the chronic mucocuta-neous candidosis of autoimmune polyendocrinopa-thy-candidosis-ectodermal dystrophy (APECED)[J]. Acta Med Scand, 1986,220(4):333-339.
[17] Kim JH, Choi WG, Moon JY , et al. Metabolomics-assisted metabolite profiling of itraconazole in human liver preparations[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2018,1083:68-74.
doi: 10.1016/j.jchromb.2018.02.041 pmid: 29524695
[18] Jachiet M, Lanternier F, Rybojad M , et al. Posacona-zole treatment of extensive skin and nail dermato-phytosis due to autosomal recessive deficiency of CARD9[J]. JAMA Dermatol, 2015,151(2):192-194.
doi: 10.1001/jamadermatol.2014.2154
[19] 曹江, 江学维, 章成 , 等. 泊沙康唑抗侵袭性真菌感染文献计量分析[J]. 中华医院感染学杂志, 2017,27(24):5537-5540.
Cao J, Jiang XW, Zhang C , et al. Quantitative analysis of posaconazole in the treatment of invasive fungal infection[J]. Chin J Nosocomiol, 2017,27(24):5537-5540.
[20] Alves de Medeiros AK, Lodewick E, Bogaert DJ , et al. Chronic and invasive fungal infections in a family with CARD9 deficiency[J]. J Clin Immunol, 2016,36(3):204-209.
doi: 10.1007/s10875-016-0255-8 pmid: 27116191
[21] Revankar SG, Nailor MD, Sobel JD , Use of terbina-fine in rare and refractory mycoses[J]. Future Micro-biol, 2008,3(1):9-17.
doi: 10.2217/17460913.3.1.9
[22] Hu Y, Hu Y, Lu Y , et al. A case report of penile infec-tion caused by fluconazole- and terbinafine-resistant Candida albicans[J]. Mycopathologia, 2017,182(3/4):397-402.
doi: 10.1007/s11046-016-0070-z
[23] Nielsen J, Kofod-Olsen E, Spaun E , et al. A STAT1-gain-of-function mutation causing Th17 deficiency with chronic mucocutaneous candidiasis, psoriasiform hyperkeratosis and dermatophytosis[J]. BMJ Case Rep, 2015, 2015: bcr2015211372.
[24] Martinez-Suarez JV, Rodriguez-Tudela JL , In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates[J]. Antimicrob Agents Chemother, 1996,40(5):1277-1279.
[25] Jayasinghe M, Schmidt S, Walker B , et al. Success-ful treatment of azoleresistant chronic mucocu-taneous candidosis with caspofungin[J]. Acta Derm Venereol, 2006,86(6):563-564.
doi: 10.2340/00015555-0165 pmid: 17106615
[26] Caínzos-Romero T, Sánchez-Trigo S, Marfil-Verchili S , et al. Treatment of chronic mucocutaneous candidia- sis, an unsolved issue. Case report and literature re-view[J]. J Clin Cell Immunol, 2017,8:501.
[27] Kirkpatrick CH , Chronic mucocutaneous candidiasis[J]. J Am Acad Dermatol, 1994,31(3 Pt 2):S14-S17.
doi: 10.1016/S0190-9622(08)81260-1
[28] Higgins E, Al Shehri T , McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal trans-ducer and activator of transcription 1 (STAT1) mutation[J]. J Allergy Clin Immunol, 2015,135(2):551-553.
doi: 10.1016/j.jaci.2014.12.1867
[29] Weinacht KG, Charbonnier LM, Alroqi F , et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 ( STAT1) gain-of-function mutation[J]. J Allergy Clin Immunol, 2017, 139(5): 1629- 1640. e2.
doi: 10.1016/j.jaci.2016.11.022
[30] Zimmerman O, Rösler B, Zerbe CS , et al. Risks of ruxolitinib in STAT1 gain-of-function-associated se- vere fungal disease[J]. Open Forum Infect Dis, 2017, 4(4): ofx202.
doi: 10.1093/ofid/ofx202 pmid: 29226168
[31] van de Veerdonk FL, Netea MG . Treatment options for chronic mucocutaneous candidiasis[J]. J Infect, 2016,72(Suppl):S56-S60.
doi: 10.1016/j.jinf.2016.04.023 pmid: 27161991
[32] Wildbaum G, Shahar E, Katz R , et al. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restora-tion of IL-17 secretion[J]. J Allergy Clin Immunol, 2013,132(3):761-764.
doi: 10.1016/j.jaci.2013.04.018
[33] Kullberg BJ, Oude Lashof AM, Netea MG , Design of efficacy trials of cytokines in combination with antifungal drugs[J]. Clin Infect Dis, 2004,39(Suppl 4):S218-S223.
doi: 10.1086/421960 pmid: 15546121
[34] van de Veerdonk FL, Koenen HJ, van der Velden WJ , et al. Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis[J]. Immunol Lett, 2015,167(1):54-56.
doi: 10.1016/j.imlet.2015.05.008 pmid: 25999307
[35] 李璟, 梁菁, 徐婷 , 等. IL-6 -572基因多态性与侵袭性牙周炎易感性的相关性研究[J]. 口腔疾病防治, 2017,25(11):718-722.
Li J, Liang J, Xu T , et al. Relationship between inter-leukin-6 -572 gene polymorphism and aggressive periodontitis in Chinese[J]. J Prevent Treatment Sto-matol Dis, 2017,25(11):718-722.
[36] Zheng J, van de Veerdonk FL, Crossland KL , et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous can-didiasis (CMC)[J]. Eur J Immunol, 2015,45(10):2834-2846.
doi: 10.1002/eji.201445344
[37] Abaza YM, Kadia TM, Jabbour EJ , et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies[J]. Cancer, 2017,123(24):4851-4859.
doi: 10.1002/cncr.v123.24
[38] Batlevi CL, Crump M, Andreadis C , et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma[J]. Br J Haematol, 2017,178(3):434-441.
doi: 10.1111/bjh.2017.178.issue-3
[39] Hoh MC, Lin HP, Chan LL , et al. Successful alloge-neic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome[J]. Bone Marrow Transplant, 1996,18(4):797-800.
[40] Aldave JC, Cachay E, Núñez L , et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation[J]. J Clin Immunol, 2013,33(8):1273-1275.
doi: 10.1007/s10875-013-9947-5
[41] Dhalla F, Fox H, Davenport EE , et al. Chronic muco-cutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility[J]. Clin Exp Immunol, 2016,184(2):216-227.
doi: 10.1111/cei.2016.184.issue-2
[42] Koo S, Kejariwal D, Al-Shehri T , et al. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation[J]. United European Gastroenterol J, 2017,5(5):625-631.
doi: 10.1177/2050640616684404
[43] Sampaio EP, Hsu AP, Pechacek J , et al. Signal trans-ducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioido-mycosis and histoplasmosis[J]. J Allergy Clin Immunol, 2013,131(6):1624-1634
doi: 10.1016/j.jaci.2013.01.052
[44] Tanimura M, Dohi K, Hirayama M , et al. Recurrent inflammatory aortic aneurysms in chronic mucocuta-neous candidiasis with a gain-of-function STAT1 mu- tation[J]. Int J Cardiol, 2015,196:88-90.
doi: 10.1016/j.ijcard.2015.05.183
[1] Wang Nannan,He Hong,Hua Fang. Research progress on the risk factors of orthodontically induced enamel demineralization [J]. Int J Stomatol, 2024, 51(1): 91-98.
[2] Han Chong,He Dongning,Yu Feiyan,Wu Dongchao. Research progress on the mechanism and treatment of pain after oral implants [J]. Int J Stomatol, 2024, 51(1): 99-106.
[3] Sun Xu,Deng Zhennan,Wen Cai,Zhao Ying. Implant surface micromorphological changes after Er: YAG laser irradiation observed under scanning electron microscope [J]. Int J Stomatol, 2023, 50(6): 669-673.
[4] Huang Yuanhong,Peng Xian,Zhou Xuedong.. Progress in research into the effect of Rhizoma Drynariae on the treatment of bone-related diseases in the oral cavity [J]. Int J Stomatol, 2023, 50(6): 679-685.
[5] Liu Yang,Yin Deqiang. Introducing a novel digital articulation workflow with high precision [J]. Int J Stomatol, 2023, 50(5): 499-505.
[6] Ji Xiao,Zhang Lan,Huang Dingming.. Diagnosis and treatment of odontogenic and non-odontogenic maxillary sinusitis [J]. Int J Stomatol, 2023, 50(5): 566-572.
[7] Zhao Yuanxi,Su Qin.. Application and development of supplementary techniques in removing the remaining filling materials of root canal retreatment [J]. Int J Stomatol, 2023, 50(5): 581-586.
[8] Gong Meiling,Cheng Xingqun,Wu Hongkun.. Research progress on the correlation between Parkinson’s disease and periodontitis [J]. Int J Stomatol, 2023, 50(5): 587-593.
[9] Liu Ting,Wu Xiuping.. Research progress on oral-craniomaxillofacial features and treatment of Down syndrome [J]. Int J Stomatol, 2023, 50(5): 618-622.
[10] Qin Yichun,Tan Xuelian,Huang Dingming.. Clinical research progress on glandular odontogenic cyst [J]. Int J Stomatol, 2023, 50(1): 100-107.
[11] Li Ting,Yang Xuecai,Wang Junwei.. Children with Williams-Beuren syndrome associated with cranial and maxillofacial deformity [J]. Int J Stomatol, 2023, 50(1): 108-113.
[12] Wang Qiqiu,Zhi Qinghui.. Research progress on treatments of enamel white spot lesions [J]. Int J Stomatol, 2022, 49(6): 717-723.
[13] Li Weiguang,Wu Yafei,Guo Shujuan.. Research progress on the use of inorganic nanoparticles in the diagnosis and treatment of periodontal disease [J]. Int J Stomatol, 2022, 49(6): 724-730.
[14] Zhu Xingrong,Liao Lan. Research progress on oral clinical diagnosis and treatment of ectodermal dysplasia syndrome [J]. Int J Stomatol, 2022, 49(6): 737-742.
[15] Zeng Yanglin,Tan Xuelian,Song Dongzhe,Huang Dingming.. Research progress on diagnosis and treatment of root resorption [J]. Int J Stomatol, 2022, 49(5): 561-568.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .